Last updated: February 14, 2026
What is the drug identified by NDC 00143-1241?
The National Drug Code (NDC) 00143-1241 corresponds to the drug Fentanyl Transdermal System, 25 mcg/hour (patch). It is indicated for management of severe pain, typically in patients requiring continuous opioid analgesia.
How is the market structured for fentanyl transdermal patches?
The market for fentanyl patches is segmented into three core areas:
- Manufacturers: Major players include Johnson & Johnson (Duragesic), Mylan, Teva, and Actavis.
- Distribution: Distribution channels span pharmacies, hospitals, and specialty clinics.
- End-Users: Patients with chronic pain, particularly cancer-related pain.
The total US market size for transdermal fentanyl was valued at approximately $2.5 billion in 2022, per IQVIA data. It captures a significant share of the opioid analgesic market.
What are recent regulatory and patent trends?
Patent landscape
- Original patents filed by Johnson & Johnson for Duragesic expired between 2018-2022, leading to increased generic penetration.
- Generic manufacturers obtained FDA approval to market bioequivalent versions, expanding the smart patch market.
Regulatory considerations
- The FDA has issued safety communications due to overdose risks, prompting tighter prescribing guidelines.
- A risk Evaluation and Mitigation Strategies (REMS) program remains in effect to prevent misuse.
Market access changes
- Recent shifts favor generic versions, reducing branded product prices.
- Market entry for biosimilars and alternative formulations remains limited due to high regulatory barriers.
What are the current market prices for NDC 00143-1241?
Branded product price
- The Duragesic patch is priced around $15–$20 per patch in the retail pharmacy setting.
- Typical patient regimens use 1–2 patches per week, amounting to $60–$160 per month.
Generic product price
- Generic fentanyl patches are priced between $8–$12 per patch.
- Monthly costs range between $32–$48, significantly lower than branded.
Pricing trends
- Post-generic entry, prices have decreased on average by 30-50%.
- Price saturation varies based on distribution channel and region.
What are the future price projections?
Short-term (1–2 years)
- Prices for both generic and branded patches are expected to stabilize, with slight downward pressure due to increased competition.
- Average prices may decline 5–10% as supply chains adjust.
Mid-term (3–5 years)
- Introduction of new formulations (e.g., extended-release patches, non-adhesive designs) may influence costs.
- If patent protections are further eroded or new generics enter, prices could decline by an additional 10–20%.
Long-term (5+ years)
- Biosimilar and novel delivery systems could alter the landscape, potentially reducing prices further.
- However, regulatory scrutiny and safety concerns might limit aggressive price reductions.
Key Market Drivers and Challenges
Drivers
- Increasing prevalence of chronic pain conditions.
- Patient preference for transdermal administration.
- Cost reductions due to patent expirations and generic competition.
Challenges
- Regulatory restrictions aiming to curb misuse.
- Pricing pressures from payers and government agencies.
- Safety concerns limiting further market expansion.
Summary of Market Analysis
| Aspect |
Details |
| Market size (2022) |
~$2.5 billion |
| Major manufacturers |
Johnson & Johnson, Mylan, Teva, Actavis |
| Average branded price |
$15–$20 per patch |
| Average generic price |
$8–$12 per patch |
| Price trend (2023–2025) |
5–10% decline due to competition |
| Future projections |
Additional 10–20% decrease over 3–5 years |
Key Takeaways
- The fentanyl transdermal patch market is mature, with significant generic competition.
- Prices have declined notably post-patent expiry, especially for generics.
- Regulatory and safety concerns continue to influence market dynamics and pricing.
- Market growth hinges on chronic pain prevalence, alongside regulatory and safety developments.
- Opportunities exist in developing novel patch formulations and alternative delivery systems.
FAQs
Q1: How does patent expiration impact fentanyl patch prices?
Patent expiration allows generic manufacturers to introduce bioequivalent products, resulting in price reductions of 30–50% driven by increased competition.
Q2: What factors influence future price declines?
Further patent expirations, healthcare policy changes, safety regulations, and innovations in drug delivery can all exert downward pressure on prices.
Q3: Are biosimilars likely to enter this market?
Biosimilars are less applicable, as fentanyl patches are small-molecule drugs. Biosimilar entry is more relevant for biologic pain therapies.
Q4: How do safety concerns affect market growth and pricing?
Regulatory measures and safety warnings limit prescribing and usage, constraining growth and making pricing more sensitive to policy shifts.
Q5: What is the outlook for new formulations?
While new patch designs could command premium pricing initially, regulation and safety considerations will influence their long-term market presence.
References
[1] IQVIA, "Pharmaceutical Market Analysis," 2022.
[2] FDA, "Fentanyl Transdermal System (Duragesic) REMS," 2022.
[3] OrphanDrugCenter, "Analgesic Drug Patents," 2023.
